RUNX2 as a promising therapeutic target for malignant tumors

References

• Blyth K, Vaillant F, Jenkins A, et al. Runx2 in normal tissues and cancer cells: a developing story. Blood Cells Mol Dis. 2010;45(2):117–123. doi:10.1016/j.bcmd.2010.05.00720580290
   PubMed Web of Science ®Google Scholar
• Chimge N, Frenkel BJ. The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene. 2013;32(17):2121–2130. doi:10.1038/onc.2012.32823045283
   PubMed Web of Science ®Google Scholar
• Hill T, Später D, Taketo M, et al. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 2005;8(5):727–738. doi:10.1016/j.devcel.2005.02.01315866163
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yasui N, Ito K, et al. A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci U S A. 2000;97(19):10549–10554. doi:10.1073/pnas.18030959710962029
   PubMed Web of Science ®Google Scholar
• Ferrari N, McDonald L, Morris J, et al. RUNX2 in mammary gland development and breast cancer. J Cell Physiol. 2013;228(6):1137–1142. doi:10.1002/jcp.2428523169547
   PubMed Web of Science ®Google Scholar
• Chimge N, Baniwal S, Luo J, et al. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res. 2012;18(3):901–911. doi:10.1158/1078-0432.Ccr-11-153022147940
   PubMed Web of Science ®Google Scholar
• Onodera Y, Miki Y, Suzuki T, et al. Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci. 2010;101(12):2670–2675. doi:10.1111/j.1349-7006.2010.01742.x20946121
   PubMed Web of Science ®Google Scholar
• Iorio M, Ferracin M, Liu C, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–7070. doi:10.1158/0008-5472.Can-05-178316103053
   PubMed Web of Science ®Google Scholar
• Miao Y, Zheng W, Li N, et al. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway. Sci Rep. 2017;7:41942. doi:10.1038/srep4194228165066
   PubMed Web of Science ®Google Scholar
• Wang F, Li L, Chen Z, et al. MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway. Int J Mol Med. 2016;37(5):1421–1428. doi:10.3892/ijmm.2016.251826951965
   PubMed Web of Science ®Google Scholar
• Tong L, Yuan Y, Wu S. Therapeutic microRNAs targeting the NF-kappa B signaling circuits of cancers. Adv Drug Deliv Rev. 2015;81:1–15. doi:10.1016/j.addr.2014.09.00425220353
   PubMed Web of Science ®Google Scholar
• Sweeney K, Cameron E, Blyth KJM, et al. Complex interplay between the RUNX transcription factors and wnt/β-catenin pathway in cancer: a tango in the night. Mol Cells. 2020;43(2):188–197. doi:10.14348/molcells.2019.031032041394
   PubMed Web of Science ®Google Scholar
• Han M, Wang F, Gu Y, et al. MicroRNA-21 induces breast cancer cell invasion and migration by suppressing smad7 via EGF and TGF-β pathways. Oncol Rep. 2016;35(1):73–80. doi:10.3892/or.2015.436026531758
   PubMed Web of Science ®Google Scholar
• Taipaleenmäki H, Browne G, Akech J, et al. Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 2015;75(7):1433–1444. doi:10.1158/0008-5472.Can-14-102625634212
   PubMed Web of Science ®Google Scholar
• Brabletz S, Bajdak K, Meidhof S, et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 2011;30(4):770–782. doi:10.1038/emboj.2010.34921224848
   PubMed Web of Science ®Google Scholar
• Wang Z, Li Y, Kong D, et al. Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett. 2010;292(2):141–148. doi:10.1016/j.canlet.2009.11.01220022691
   PubMed Web of Science ®Google Scholar
• Liu X, Zhao T, Bai X, et al. LOC101930370/MiR-1471 axis modulates the hedgehog signaling pathway in breast cancer. Cell Physiol Biochem. 2018;48(3):1139–1150. doi:10.1159/00049198030041193
   PubMedGoogle Scholar
• Pranavkrishna S, Sanjeev G, Akshaya R, et al. Regulation of Runx2 and its signaling pathways by microRNAs in breast cancer metastasis. Curr Protein Pept Sci. 2020;21. doi:10.2174/1389203721666201116115337
   Web of Science ®Google Scholar
• Bhadury J, Nilsson L, Muralidharan S, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U S A. 2014;111(26):E2721–2730. doi:10.1073/pnas.140672211124979794
   PubMed Web of Science ®Google Scholar
• Sancisi V, Manzotti G, Gugnoni M, et al. RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN. Nucleic Acids Res. 2017;45(19):11249–11267. doi:10.1093/nar/gkx80228981843
   PubMed Web of Science ®Google Scholar
• van der Deen M, Akech J, Lapointe D, et al. Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility. J Biol Chem. 2012;287(7):4503–4517. doi:10.1074/jbc.M111.28777122158627
   PubMed Web of Science ®Google Scholar
• Kim B, Kim H, Jung S, et al. A CTGF-RUNX2-RANKL axis in breast and prostate cancer cells promotes tumor progression in bone. J Bone Miner Res. 2020;35(1):155–166. doi:10.1002/jbmr.386931505052
   PubMed Web of Science ®Google Scholar
• Li J, Cai S, Peng J, et al. Time dependent distribution of MicroRNA 144 after intravenous delivery. Microrna. 2016;5(1):36–49. doi:10.2174/221153660566616032215214627001183
   PubMedGoogle Scholar
• Tandon M, Othman A, Ashok V, et al. The role of Runx2 in facilitating autophagy in metastatic breast cancer cells. J Cell Physiol. 2018;233(1):559–571. doi:10.1002/jcp.2591628345763
   PubMed Web of Science ®Google Scholar
• Sadikovic B, Thorner P, Chilton-Macneill S, et al. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer. 2010;10:202. doi:10.1186/1471-2407-10-20220465837
   PubMed Web of Science ®Google Scholar
• Li N, Luo D, Hu X, et al. RUNX2 and Osteosarcoma. Anticancer Agents Med Chem. 2015;15(7):881–887. doi:10.2174/187152061566615030415122825738872
   PubMed Web of Science ®Google Scholar
• Ling Z, Fan G, Yao D, et al. MicroRNA-150 functions as a tumor suppressor and sensitizes osteosarcoma to doxorubicin-induced apoptosis by targeting RUNX2. Exp Ther Med. 2020;19(1):481–488. doi:10.3892/etm.2019.823131897096
   PubMed Web of Science ®Google Scholar
• Sheng K, Li YJE, Medicine T. LncRNA TUG1 promotes the development of osteosarcoma through RUNX2. Exp Ther Med. 2019;18(4):3002–3008. doi:10.3892/etm.2019.788031555384
   PubMed Web of Science ®Google Scholar
• Jia F, Zhang Z, Zhang X. MicroRNA-338-3p inhibits tumor growth and metastasis in osteosarcoma cells by targeting RUNX2/CDK4 and inhibition of MAPK pathway. J Cell Biochem. 2019;120(4):6420–6430. doi:10.1002/jcb.2792930484892
   PubMed Web of Science ®Google Scholar
• Wang W, Luo P, Guo W, et al. LncRNA SNHG20 knockdown suppresses the osteosarcoma tumorigenesis through the mitochondrial apoptosis pathway by miR-139/RUNX2 axis. Biochem Biophys Res Commun. 2018;503(3):1927–1933. doi:10.1016/j.bbrc.2018.07.13730072099
   PubMed Web of Science ®Google Scholar
• Pan B, Wu L, Pan L, et al. Up-regulation of microRNA-340 promotes osteosarcoma cell apoptosis while suppressing proliferation, migration, and invasion by inactivating the CTNNB1-mediated Notch signaling pathway. Biosci Rep. 2018;38(4). doi:10.1042/bsr20171615
   Web of Science ®Google Scholar
• Xie Y, Sun W, Deng Z, et al. MiR-302b suppresses osteosarcoma cell migration and invasion by targeting Runx2. Sci Rep. 2017;7(1):13388. doi:10.1038/s41598-017-13353-929042587
   PubMed Web of Science ®Google Scholar
• Lin W, Zhu X, Yang S, et al. MicroRNA-203 inhibits proliferation and invasion, and promotes apoptosis of osteosarcoma cells by targeting Runt-related transcription factor 2. Biomed Pharmacother. 2017;91:1075–1084. doi:10.1016/j.biopha.2017.05.03428525948
   PubMed Web of Science ®Google Scholar
• Zhang C, Long F, Wan J, et al. MicroRNA-205 acts as a tumor suppressor in osteosarcoma via targeting RUNX2. Oncol Rep. 2016;35(6):3275–3284. doi:10.3892/or.2016.470027035764
   PubMed Web of Science ®Google Scholar
• Alegre F, Ormonde A, Godinez D, et al. The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma. Vet Comp Oncol. 2020;18(1):52–63. doi:10.1111/vco.1252631381810
   PubMed Web of Science ®Google Scholar
• Wang X, Qin G, Liang X, et al. Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma. Nat Commun. 2020;11(1):1141. doi:10.1038/s41467-020-14870-432111827
   PubMed Web of Science ®Google Scholar
• Montazeri-Najafabady N, Dabbaghmanesh M, Chatrabnous N, et al. The effects of astaxanthin on proliferation and differentiation of MG-63 osteosarcoma cells via Aryl Hydrocarbon Receptor (AhR) pathway: a comparison with AhR endogenous ligand. Nutr Cancer. 2020;72(8):1400–1410. doi:10.1080/01635581.2019.167919931847600
   PubMed Web of Science ®Google Scholar
• Robinson D, Van Allen E, Wu Y, et al. Integrative clinical genomics of advanced prostate cancer. Cell Physiol Biochem. 2015;161(5):1215–1228. doi:10.1016/j.cell.2015.05.001
   Google Scholar
• Akech J, Wixted J, Bedard K, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene. 2010;29(6):811–821. doi:10.1038/onc.2009.38919915614
   PubMed Web of Science ®Google Scholar
• Senbanjo L, AlJohani H, AlQranei M, et al. Identification of sequence-specific interactions of the CD44-intracellular domain with RUNX2 in the transcription of matrix metalloprotease-9 in human prostate cancer cells. Cancer Drug Resist. 2020;3(3):586–602. doi:10.20517/cdr.2020.2133062960
   PubMedGoogle Scholar
• Zhang H, Pan Y, Zheng L, et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res. 2011;71(9):3257–3267. doi:10.1158/0008-5472.Can-10-260321505104
   PubMed Web of Science ®Google Scholar
• Yang Y, Bai Y, He Y, et al. PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer. Clin Cancer Res. 2018;24(4):834–846. doi:10.1158/1078-0432.Ccr-17-200629167276
   PubMed Web of Science ®Google Scholar
• Colden M, Dar A, Saini S, et al. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Cell Death Dis. 2017;8(1):e2572. doi:10.1038/cddis.2017.1528125091
   PubMed Web of Science ®Google Scholar
• Ge C, Zhao G, Li Y, et al. Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. Oncogene. 2016;35(3):366–376. doi:10.1038/onc.2015.9125867060
   PubMed Web of Science ®Google Scholar
• Sase T, Suzuki T, Miura K, et al. Runt-related transcription factor 2 in human colon carcinoma: a potent prognostic factor associated with estrogen receptor. Int J Cancer. 2012;131(10):2284–2293. doi:10.1002/ijc.2752522396198
   PubMed Web of Science ®Google Scholar
• Wai P, Mi Z, Gao C, et al. Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. J Biol Chem. 2006;281(28):18973–18982. doi:10.1074/jbc.M51196220016670084
   PubMed Web of Science ®Google Scholar
• Georges R, Adwan H, Zhivkova M, et al. Regulation of osteopontin and related proteins in rat CC531 colorectal cancer cells. Int J Oncol. 2010;37(2):249–256. doi:10.3892/ijo_0000067220596651
   PubMed Web of Science ®Google Scholar
• Dacheng W, Songhe L, Weidong J, et al. LncRNA SNHG3 promotes the growth and metastasis of colorectal cancer by regulating miR-539/RUNX2 axis. Biomed Pharmacother. 2020;125:110039. doi:10.1016/j.biopha.2020.11003932187965
   PubMed Web of Science ®Google Scholar
• Ji Q, Cai G, Liu X, et al. MALAT1 regulates the transcriptional and translational levels of proto-oncogene RUNX2 in colorectal cancer metastasis. Cell Death Dis. 2019;10(6):378. doi:10.1038/s41419-019-1598-x31097689
   PubMed Web of Science ®Google Scholar
• Chai J, Guo D, Ma W, et al. A feedback loop consisting of RUNX2/LncRNA-PVT1/miR-455 is involved in the progression of colorectal cancer. Am J Cancer Res. 2018;8(3):538–550.29637007
   PubMed Web of Science ®Google Scholar
• Chai J, Wang S, Han D, et al. MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase. Tumour Biol. 2015;36(2):1313–1321. doi:10.1007/s13277-014-2766-325355599
   PubMed Web of Science ®Google Scholar
• Guo Z, Yang L, Qian F, et al. Transcription factor RUNX2 up-regulates chemokine receptor CXCR4 to promote invasive and metastatic potentials of human gastric cancer. Oncotarget. 2016;7(15):20999–21012. doi:10.18632/oncotarget.823627007162
   PubMedGoogle Scholar
• Fu J, Zhao W, Guo D, et al. LncRNA E2F-mediated cell proliferation enhancing lncRNA regulates cancer cell behaviors and affects prognosis of gastric cancer. Dig Dis Sci. 2020;65(5):1348–1354. doi:10.1007/s10620-019-05855-531584135
   PubMed Web of Science ®Google Scholar
• Jin W, Han H, Liu D. Downregulation miR-539 is associated with poor prognosis of gastric cancer patients and aggressive progression of gastric cancer cells. Cancer Biomark. 2019;26(2):183–191. doi:10.3233/cbm-19038431403943
   PubMed Web of Science ®Google Scholar
• Zhou S, Zhang S, Wang L, et al. BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling. Oncogenesis. 2020;9(3):33. doi:10.1038/s41389-020-0218-z32157097
   PubMed Web of Science ®Google Scholar
• Li H, Zhou R, Zhang G, et al. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study. Tumour Biol. 2013;34(3):1807–1812. doi:10.1007/s13277-013-0720-423471668
   PubMedGoogle Scholar
• Yang D, Lu H, Chen G, et al. Integrated expression analysis revealed RUNX2 upregulation in lung squamous cell carcinoma tissues. IET Syst Biol. 2020;14(5):252–260. doi:10.1049/iet-syb.2020.006333095746
   PubMed Web of Science ®Google Scholar
• Yang D, Huang W, Chen G, et al. Clinical significance of transcription factor RUNX2 in lung adenocarcinoma and its latent transcriptional regulating mechanism. Comput Biol Chem. 2020;89:107383. doi:10.1016/j.compbiolchem.2020.10738333032037
   PubMed Web of Science ®Google Scholar
• Bednarek A, Laflin K, Daniel R, et al. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res Treat. 2000;60(8):2140–2145. doi:10.1016/S0165-4608(99)00201-0
   Web of Science ®Google Scholar
• Zheng Q, Zhou Y, You Q, et al. WWOX inhibits the invasion of lung cancer cells by downregulating RUNX2. Cancer Gene Ther. 2016;23(12):433–438. doi:10.1038/cgt.2016.5927834355
   PubMed Web of Science ®Google Scholar
• Hsu Y, Huang M, Yang C, et al. Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway. J Biol Chem. 2011;286(43):37335–37346. doi:10.1074/jbc.M111.25615621885439
   PubMed Web of Science ®Google Scholar
• Zhou M, Zhang L, Song M, et al. MicroRNA-218 prevents lung injury in sepsis by inhibiting RUNX2. Eur Rev Med Pharmacol Sci. 2018;22(23):8438–8446. doi:10.26355/eurrev_201812_1654330556885
   PubMed Web of Science ®Google Scholar
• Wu L, Sun L, Hua Y, et al. Overexpression of long non-coding RNA H19 protects lung fibroblasts from LPS-induced injury by targeting miR-181a and Runx2 via activation of Notch and JNK pathways. J Cell Biochem. 2018. doi:10.1002/jcb.26660
   Web of Science ®Google Scholar
• Perduca M, Dalle Carbonare L, Bovi M, et al. Runx2 downregulation, migration and proliferation inhibition in melanoma cells treated with BEL β-trefoil. Oncol Rep. 2017;37(4):2209–2214. doi:10.3892/or.2017.549328350114
   PubMed Web of Science ®Google Scholar
• Deiana M, Dalle Carbonare L, Serena M, et al. New insights into the runt domain of RUNX2 in melanoma cell proliferation and migration. Cells. 2018;7(11):220. doi:10.3390/cells7110220
   PubMed Web of Science ®Google Scholar
• Cecconi D, Brandi J, Manfredi M, et al. Runx2 stimulates neoangiogenesis through the Runt domain in melanoma. Sci Rep. 2019;9(1):8052. doi:10.1038/s41598-019-44552-131142788
   PubMed Web of Science ®Google Scholar
• Deiana M, Dalle Carbonare L, Serena M, et al. A potential role of RUNX2- RUNT domain in modulating the expression of genes involved in bone metastases: an in vitro study with melanoma cells. Cells. 2020;9(3):751. doi:10.3390/cells9030751
   PubMed Web of Science ®Google Scholar
• Valenti M, Dalle Carbonare L, Mottes MJ. RUNX2Ectopic expression of the osteogenic master gene in melanoma. World J Stem Cells. 2018;10(7):78–81. doi:10.4252/wjsc.v10.i7.7830079129
   PubMed Web of Science ®Google Scholar
• Dalle Carbonare L, Frigo A, Francia G, et al. Runx2 mRNA expression in the tissue, serum, and circulating non-hematopoietic cells of patients with thyroid cancer. J Clin Endocrinol Metab. 2012;97(7):E1249–1256. doi:10.1210/jc.2011-262422511796
   PubMed Web of Science ®Google Scholar
• Baniwal S, Khalid O, Gabet Y, et al. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer. 2010;9:258. doi:10.1186/1476-4598-9-25820863401
   PubMed Web of Science ®Google Scholar
• Bolf E, Gillis N, Barnum M, et al. The thyroid hormone receptor-RUNX2 axis: a novel tumor suppressive pathway in breast cancer. Horm Cancer. 2020;11(1):34–41. doi:10.1007/s12672-019-00373-231865591
   PubMed Web of Science ®Google Scholar
• Rossi T, Pistoni M, Sancisi V, et al. RAIN is a novel enhancer-associated lncRNA that controls RUNX2 expression and promotes breast and thyroid cancer. Mol Cancer Res. 2020;18(1):140–152. doi:10.1158/1541-7786.Mcr-19-056431624086
   PubMed Web of Science ®Google Scholar
• Han M, Chen L, Wang YJO, et al. miR-218 overexpression suppresses tumorigenesis of papillary thyroid cancer via inactivation of PTEN/PI3K/AKT pathway by targeting Runx2. Onco Targets Ther. 2018;11:6305–6316. doi:10.2147/ott.S17215230319270
   PubMed Web of Science ®Google Scholar
• Akbari-Birgani S, Paranjothy T, Zuse A, et al. Cancer stem cells, cancer-initiating cells and methods for their detection. Drug Discovery Today. 2016;21(5):836–842. doi:10.1016/j.drudis.2016.03.00426976692
   PubMed Web of Science ®Google Scholar
• Clouston H, Rees P, Lamb R, et al. Effect of tissue factor on colorectal cancer stem cells. Anticancer Res. 2018;38(5):2635–2642. doi:10.21873/anticanres.1250529715083
   PubMed Web of Science ®Google Scholar
• Pindiprolu S, Krishnamurthy P. Chintamaneni PJN-Ssaop. Pharmacological targets of breast cancer stem cells: a review. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(5):463–479. doi:10.1007/s00210-018-1479-329476201
   PubMed Web of Science ®Google Scholar
• Skvortsov S, Skvortsova I, Tang D, et al. Concise Review: prostate Cancer Stem Cells: current Understanding. Stem Cells. 2018;36(10):1457–1474. doi:10.1002/stem.285929845679
   PubMed Web of Science ®Google Scholar
• Jing F, Kim H, Kim C, et al. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases. Int J Oncol. 2015;46(4):1582–1588. doi:10.3892/ijo.2015.284425625240
   PubMed Web of Science ®Google Scholar
• Wang L, Park P, La Marca F, et al. Bone formation induced by BMP-2 in human osteosarcoma cells. Int J Oncol. 2013;43(4):1095–1102. doi:10.3892/ijo.2013.203023900689
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu L, Xu X, et al. miR-205/RunX2 axis negatively regulates CD44/CD24 breast cancer stem cell activity. Am J Cancer Res. 2020;10(6):1871–1887.32642297
   PubMed Web of Science ®Google Scholar
• Liao C, Adisetiyo H, Liang M, et al. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res. 2010;70(18):7294–7303. doi:10.1158/0008-5472.Can-09-398220807814
   PubMed Web of Science ®Google Scholar